Leadership and
Scientific Advisory Board

John Gu joined Crown Bioscience from WuXi Nextcode, a global leader in genomic data analysis, where he was General Manager for the China business, as well as Chief Digital Officer. Prior to Wuxi Nextcode, John was Managing Director for Silver Sand Technologies, a consultancy in digital transformation, and Chief Information Officer for Baidu, the leading internet search engine in China. He held successive senior technology and operations positions at Alcatel-Lucent in Europe and the US. John has played key roles in global business and operational transformation and the growth of various technology platforms. John holds an MBA from the University of Chicago, an MS in Computer Science from Loyola University of Chicago, and a double-major BS in Computer Science and Electrical Engineering from Shanghai Jiao Tong University.

Eva Ho is responsible for leading the company’s global finance organization and serves as a member of the company’s Executive Committee. Eva joined Crown Bioscience in June 2016 as Chief Financial Officer.

Eva has extensive finance leadership experience at multinational corporations across several industries. Before joining Crown Bioscience, she served as CFO for TWi Pharmaceuticals, CFO and Spokesperson for Acer Computer, and EVP and CFO for The Test Rite Group. Prior to that, she held senior finance positions with Sun Microsystems, Inc. and Oracle.

Eva holds an MBA degree in accounting from the University of Denver, and a bachelor’s degree in Economics from National Taiwan University. Eva is a certified public accountant in the state of Colorado, USA.

Alex Slater joined the business in 2021 after working at several different CROs that supported all phases of drug discovery and development.

Throughout his 27 career in business development, Alex has worked with large CROs, such as Covance (LabCorp Drug Development), where he supported Europe and Asia Pacific business development teams selling central laboratory services in support of clinical trials. Alex has also led global business development teams at Eurofins Discovery and served as the VP of Business Development and GM of Europe for Science Exchange, a Silicon Valley start-up.

Alex holds a BSc degree in Medical Biochemistry from the University of Surrey.

Shirley Huang leads Crown Bioscience’s human resources, driving strategic programs in Crown Bioscience and the JSR Life Sciences group of companies.

Shirley has deep HR leadership experience in multinational companies in multiple industries. Before joining Crown Bioscience, Shirley was the Regional HR Director, Strategic Markets (APAC, EMEA, Brazil South America) for clinical diagnostics company DiaSorin S.p.A. Before that, Shirley was the Regional HR Director under Sonepar Group, a global B2B distributor of electrical/automation products and solutions. Prior to this Shirley worked for a prominent US-based Human Capital Consulting Firm.

Shirley holds dual MBA's from BI Norwegian Business School and Fudan University. Shirley also holds advanced qualifications in Human Resource Management from the Manchester Metropolitan University and Executive Leadership from the Kellogg School of Management.

Luke works as the Senior Vice President of Crown Bioscience’s Global Scientific Operations, where he oversees a wide array of discovery processes in vivo, in vitro, and biologicals, alongside veterinary affairs. Before joining Crown Bioscience, Luke was the Global Head of Pharmacology at Biocytogen, steering the preclinical and translational pharmacology divisions to enhance R&D and CRO services worldwide. He has significantly contributed to Gemini Pharmaceuticals, Achillion Pharmaceuticals, and Alexion Pharmaceuticals, where he played a key role in advancing numerous drug programs from preclinical studies to clinical trials, leading to several of them receiving market approval.

Luke brings over two decades of experience across various therapeutic areas, including oncology and immuno-oncology, with expertise in target identification, lead selection, and drug progression to Investigational New Drug (IND) submissions. His knowledge covers diverse therapeutic modalities like antibodies, biologics, and small molecules. Luke holds a PhD in Neurobiology from Sun Yat-Sen University of Medical Sciences and an M.D. from Hubei Medical University, reinforcing his academic foundation with research positions at Emory University, Yale University, and Harvard Boston Children’s Hospital.

Davy Ouyang is a seasoned biotech executive and scientific leader with over 20 years of experience in drug discovery and preclinical development across oncology, immuno-oncology, and autoimmune diseases. Davy serves as SVP of Innovation at Crown Bioscience following roles as Executive Vice President of R&D at Sidewinder Therapeutics and Vice President of Biology at InnoCare Pharma. Earlier in his career, Davy held research scientist positions at Merck & Co. and the Cancer Institute of New Jersey.

Dr. Ouyang has significant experience driving first-in-class ADC and biologics programs and a strong track record of advancing innovative drug candidates, including more than 20 IND-enabling molecules and 10 IND approvals across small molecules and biologics. Davy has extensive research experience, particularly in the areas of translational oncology, preclinical pharmacology, and platform development with a strong academic foundation and 44 peer-reviewed publications.

He received his PhD in Cancer Biology from the University of Hong Kong and completed postdoctoral training in oncology pharmacology with Dr. Cory Abate-Shen at Rutgers University.

Nalini Murdter has over 25 years experience in the biotech industry. Her career spans early stage as well as large established global businesses across life sciences and diagnostics markets. Nalini joined Crown Bioscience in 2019 as SVP, General Manager, US & Europe. Prior to joining the company, she held positions as President and CEO of MBL International, a JSR Life Sciences company, and Chief Business Officer at NanoString Technologies, Inc.

Nalini has held senior global management positions at Agilent Technologies in Marketing, Acquisitions, Alliances and Venture Investments and Business Development. Prior to Agilent, Nalini was the Director of Product and Business Development at Adeza Biomedical Corp., a women’s healthcare company, which is now a part of Hologic, Inc. She has served on non-profit and advisory boards of start-up companies.

Nalini was a Senior Research Fellow in the Division of Biology at California Institute of Technology in Pasadena, California. She has a PhD in Biochemistry from the University of Maryland, College Park and an MBA from the Haas School of Business at University of California, Berkeley, California.

Ludovic Bourré leads the Crown Bioscience Research and Innovation team, leveraging experience in the CRO/biotech industry and expertise in the preclinical development of oncology drugs and vaccines. Prior to this role, Ludovic held various positions in preclinical CROs working on oncology research program management and the development of imaging platforms. He has also worked in a hospital setting, collaborating with clinicians to develop a translational preclinical oncology platform for PDX and humanized mice.

Ludovic’s move to industry began with leading the preclinical and clinical evaluation of immuno-oncology programs, developing cancer vaccines and antibody therapies, from preclinical to phase I/IIa in hematological and solid tumor cancers. As the head of the pharmacology department, he was responsible for conducting POC and non-clinical evaluations for the different programs as well as managing the preparation and presentation of non-clinical pharmacology sections of external documents.

Ludovic earned a postdoc in Pharmacology and Drug Delivery Systems from the University College Cork, Ireland and University College London, UK.

Chen Gao joined Crown Bioscience from WuXi Nextcode, a global leader in genomic data analysis, where he served as Director of Product Management, focusing on the commercialization of population cohort data and pharma biomarker testing services.

Throughout his commercial career, Chen has held progressive product and innovation management roles within either regional or global teams of several established life science and in vitro diagnostic companies, including Thermo Fisher Scientific, Roche Molecular Diagnostics, Becton Dickinson, and Siemens Diagnostics. He honed his strategic skills while serving as a Senior Consultant at Deloitte (Monitor) Consulting, advising clients in the life science and pharma industries.

Prior to his corporate career, Chen completed a rigorous three-year internship at the Air Force General Hospital in Beijing after receiving a medical degree majoring in experimental medicine from the Third Military Medical University in Chongqing, China. Complementing his medical background, Chen holds an MBA from Kenan-Flagler Business School, University of North Carolina, Chapel Hill, and a master degree in Chemical Engineering with a focus on bioprocessing control from the University of Southern Denmark.

Dr. Julie Mayer joined Crown Bioscience from NeoGenomics Laboratories, where she served as Vice President of Molecular Strategy, overseeing the R&D organization largely focused on developing comprehensive, high-throughput NGS and novel technology/applications.

Dr. Mayer has held progressive scientific and leadership roles spanning R&D and Operations at several molecular diagnostics companies, including NeoGenomics Laboratories, Biocept Inc., Navigate BioPharma Services (a Novartis subsidiary), Genoptix (a former Novartis subsidiary), Menarini Silicon Biosystems, and Quest. She has extensive precision medicine experience, having developed, validated, and launched >50 diagnostic assays for production and clinical trial testing in multiple CLIA/CAP accredited laboratories.

Before joining industry, Dr. Mayer received her post-doctoral training in translational breast cancer research at Baylor College of Medicine and in clinical cancer prevention at MD Anderson Cancer Center.

Dr. Mayer obtained her Ph.D in Pathology and Master’s of Science in Experimental and Molecular Pathology both from the University of Southern California, and a Bachelor’s degree in Biology from the University of California Riverside.

Dr. Sheng Guo leads the Data Science and Bioinformatics team at Crown Bioscience, bringing with him extensive experience from his previous roles at Boehringer Ingelheim Pharmaceutical Inc. and Syngenta. 

Dr. Guo’s current research interests are tumor model omics, preclinical statistics, biomarker discovery, NGS product design, AI imaging analysis, and bioinformatics software development. Dr. Guo has authored more than 50 abstracts and manuscripts, with recent major-author papers in Cancer Research, Cancer Research Communications, NAR Genomics and Bioinformatics, and BMC Cancer, amongst others.

Dr. Guo received his PhD in Genomics and Computational Biology from the University of Pennsylvania, and his BSc in Biochemistry from Nankai University.

Amy Musolino leads the Crown Bioscience Marketing & Product Management teams, bringing over 20 years of experience in global strategic product management and digital marketing communications across multiple stages of drug development.

Amy brings a unique perspective, having leveraged experience in marketing and product management of lab chemicals and bulk pharmaceutical excipient manufacturing to e-clinical platforms, Phase II/III CRO experience, clinical supplies, post-launch commercial services, medical devices, and pharmaceutical drug marketing. In her previous role at GE HealthCare, she built a team to deliver the first ever digital marketing organization for its pharmaceutical diagnostics division. Prior to that, she built a USCAN marketing organization for IQVIA and previously served as the global strategic director of marketing and new services development for a division of Thermo Fisher Scientific. Other tenures include roles at Covance and Mallinckrodt Baker.

With experience at leading Fortune 500 companies, Amy brings the rigor of process improvement methodologies while at the same time encouraging teams to embrace creative approaches to disruptive communication and technologies, routinely speaking on the future of AI in drug development.

Amy earned an MBA in Marketing and a Certificate in Supply Chain Management from Lehigh University, as well as a BS in Engineering from Cornell University.

Maria Radino leads Crown Bioscience's Global Quality Assurance and Regulatory Compliance program, leveraging over 25 years of experience in the GxP arena. Her career has included key positions at numerous global CROs. In these roles, she has been responsible for implementing quality management systems that effectively and efficiently monitor quality, integrity, and regulatory compliance across various operations such as large and small molecule bioanalysis, preclinical studies, agrochemicals, animal health, and software systems validation.

Previously, she worked as the Executive Director of Quality Assurance at Wuxi AppTec/Xenobiotic Laboratories. Maria holds a BSc in Biochemistry from Concordia University and is an active member of the Chemical Institute of Canada, the American Chemical Society, as well as the Society of Quality Assurance.

At Crown Bioscience, Maria oversees quality and regulatory initiatives, including Environmental, Health, and Safety (EHS) and animal welfare, to ensure adherence to compliance and operational corporate standards and uphold the highest standards of quality and scientific integrity in our products and services.